Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): Distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea

P. Bernasconi, M. Boni, P. M. Caviglianio, S. Calatroni, E. Brusamolino, F. Passamonti, G. Volpe, A. Pistorio, I. Giardini, B. Rocca, M. Caresana, M. Lazzarino, C. Bernasconi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous (32P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the longterm safety of hydroxyurea (HU). Pipobroman (PI), a well tolerated and simple to use drug, constitutes a valid alternative to those cytoreductive treatments. The present study reports on 155 ET patients treated at our institution from 1985 to 1995, and monitored until December 2000. A good control of thrombocytosis was achieved with PI as the only treatment in 106 patients and With HU in 23 patients. Twenty-six patients received no treatment. After a median follow-up of 104 months, seven patients (four treated with HU, and three with PI) developed AML whereas one patient treated with PI developed MDS. A significant difference in progression-free survival was observed between HU- and PI-treated patients (P = 0.004). A short-arm deletion of chromosome 17 was most frequently detected in HU-treated patients, while a long-arm trisomy of chromosome 1 and a monosomy 7q were seen in PI-treated patients. No TP53 mutation was discovered in the six patients studied (two HU-treated and four PI-treated). We conclude that these cytogenetic abnormalities are not linked to the natural history of the disease, but rather that they might be induced by the cytoreductive treatment.

Original languageEnglish
Pages (from-to)2078-2083
Number of pages6
JournalLeukemia
Volume16
Issue number10
DOIs
Publication statusPublished - Oct 1 2002

Fingerprint

Pipobroman
Essential Thrombocythemia
Hydroxyurea
Acute Myeloid Leukemia
Chromosome Aberrations
Myelodysplastic Syndromes
Monosomy
Thrombocytosis
Busulfan
Myeloproliferative Disorders
Chromosomes, Human, Pair 1
Alkylating Agents
Trisomy
Therapeutics

Keywords

  • 17p-
  • Chromosome abnormalities
  • Cytogenetics
  • FISH
  • TP53

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET) : Distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. / Bernasconi, P.; Boni, M.; Caviglianio, P. M.; Calatroni, S.; Brusamolino, E.; Passamonti, F.; Volpe, G.; Pistorio, A.; Giardini, I.; Rocca, B.; Caresana, M.; Lazzarino, M.; Bernasconi, C.

In: Leukemia, Vol. 16, No. 10, 01.10.2002, p. 2078-2083.

Research output: Contribution to journalArticle

Bernasconi, P. ; Boni, M. ; Caviglianio, P. M. ; Calatroni, S. ; Brusamolino, E. ; Passamonti, F. ; Volpe, G. ; Pistorio, A. ; Giardini, I. ; Rocca, B. ; Caresana, M. ; Lazzarino, M. ; Bernasconi, C. / Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET) : Distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. In: Leukemia. 2002 ; Vol. 16, No. 10. pp. 2078-2083.
@article{af1b6a259d424eb6afb03ca44496dceb,
title = "Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): Distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea",
abstract = "ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous (32P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the longterm safety of hydroxyurea (HU). Pipobroman (PI), a well tolerated and simple to use drug, constitutes a valid alternative to those cytoreductive treatments. The present study reports on 155 ET patients treated at our institution from 1985 to 1995, and monitored until December 2000. A good control of thrombocytosis was achieved with PI as the only treatment in 106 patients and With HU in 23 patients. Twenty-six patients received no treatment. After a median follow-up of 104 months, seven patients (four treated with HU, and three with PI) developed AML whereas one patient treated with PI developed MDS. A significant difference in progression-free survival was observed between HU- and PI-treated patients (P = 0.004). A short-arm deletion of chromosome 17 was most frequently detected in HU-treated patients, while a long-arm trisomy of chromosome 1 and a monosomy 7q were seen in PI-treated patients. No TP53 mutation was discovered in the six patients studied (two HU-treated and four PI-treated). We conclude that these cytogenetic abnormalities are not linked to the natural history of the disease, but rather that they might be induced by the cytoreductive treatment.",
keywords = "17p-, Chromosome abnormalities, Cytogenetics, FISH, TP53",
author = "P. Bernasconi and M. Boni and Caviglianio, {P. M.} and S. Calatroni and E. Brusamolino and F. Passamonti and G. Volpe and A. Pistorio and I. Giardini and B. Rocca and M. Caresana and M. Lazzarino and C. Bernasconi",
year = "2002",
month = "10",
day = "1",
doi = "10.1038/sj.leu.2402638",
language = "English",
volume = "16",
pages = "2078--2083",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET)

T2 - Distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea

AU - Bernasconi, P.

AU - Boni, M.

AU - Caviglianio, P. M.

AU - Calatroni, S.

AU - Brusamolino, E.

AU - Passamonti, F.

AU - Volpe, G.

AU - Pistorio, A.

AU - Giardini, I.

AU - Rocca, B.

AU - Caresana, M.

AU - Lazzarino, M.

AU - Bernasconi, C.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous (32P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the longterm safety of hydroxyurea (HU). Pipobroman (PI), a well tolerated and simple to use drug, constitutes a valid alternative to those cytoreductive treatments. The present study reports on 155 ET patients treated at our institution from 1985 to 1995, and monitored until December 2000. A good control of thrombocytosis was achieved with PI as the only treatment in 106 patients and With HU in 23 patients. Twenty-six patients received no treatment. After a median follow-up of 104 months, seven patients (four treated with HU, and three with PI) developed AML whereas one patient treated with PI developed MDS. A significant difference in progression-free survival was observed between HU- and PI-treated patients (P = 0.004). A short-arm deletion of chromosome 17 was most frequently detected in HU-treated patients, while a long-arm trisomy of chromosome 1 and a monosomy 7q were seen in PI-treated patients. No TP53 mutation was discovered in the six patients studied (two HU-treated and four PI-treated). We conclude that these cytogenetic abnormalities are not linked to the natural history of the disease, but rather that they might be induced by the cytoreductive treatment.

AB - ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous (32P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the longterm safety of hydroxyurea (HU). Pipobroman (PI), a well tolerated and simple to use drug, constitutes a valid alternative to those cytoreductive treatments. The present study reports on 155 ET patients treated at our institution from 1985 to 1995, and monitored until December 2000. A good control of thrombocytosis was achieved with PI as the only treatment in 106 patients and With HU in 23 patients. Twenty-six patients received no treatment. After a median follow-up of 104 months, seven patients (four treated with HU, and three with PI) developed AML whereas one patient treated with PI developed MDS. A significant difference in progression-free survival was observed between HU- and PI-treated patients (P = 0.004). A short-arm deletion of chromosome 17 was most frequently detected in HU-treated patients, while a long-arm trisomy of chromosome 1 and a monosomy 7q were seen in PI-treated patients. No TP53 mutation was discovered in the six patients studied (two HU-treated and four PI-treated). We conclude that these cytogenetic abnormalities are not linked to the natural history of the disease, but rather that they might be induced by the cytoreductive treatment.

KW - 17p-

KW - Chromosome abnormalities

KW - Cytogenetics

KW - FISH

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=0036797010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036797010&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402638

DO - 10.1038/sj.leu.2402638

M3 - Article

C2 - 12357360

AN - SCOPUS:0036797010

VL - 16

SP - 2078

EP - 2083

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -